We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Illumina Acquires Advanced Liquid Logic as Key Component for Next-Generation Genomic Solutions

By LabMedica International staff writers
Posted on 29 Jul 2013
Illumina, Inc. (San Diego, CA, USA) has announced its acquisition of Advanced Liquid Logic (ALL; Research Triangle Park, NC, USA), a leading provider of liquid handling solutions. ALL, now a wholly owned subsidiary of Illumina, has developed a proprietary “digital microfluidics” technology based on electrowetting that precisely manipulates small droplets within a sealed disposable cartridge to perform complex laboratory protocols. This technology will be used to enable Illumina to deliver a highly efficient sample-to-answer next-generation sequencing (NGS) workflow to advance diagnostic and research genomics.

“For our research customers, ALL’s technology will further streamline the industry's simplest NGS workflow, while for clinical and applied markets, where ease of use and consistency are especially valued, it will allow us to offer integrated, end-to-end solutions,” said Christian Henry, Senior Vice President and General Manager of Illumina’s Genomic Solutions business; “ALL brings an impressive IP portfolio in digital microfluidics and a talented team with a track record of innovation.”

One of Illumina's goals is to provide customers with a holistic set of tools to quickly and easily go from biological sample to answer, minimizing the risk of errors, and reducing hands-on time in the lab. To that end, Illumina announced it is collaborating with leading vendors of liquid handling robotic platforms to make automation solutions for high-throughput sample preparation more accessible. With its acquisition of ALL, Illumina will be able to introduce similar benefits to its low- and mid-throughput customers. ALL’s versatile technology has been demonstrated across numerous applications, including nucleic acid isolation from various sample types and library generation for NGS. Its robust solution has an advantage in precisely handling low sample volumes, an increasingly important focus for clinical and research laboratories.

Related Links:

Illumina, Inc.
Advanced Liquid Logic
ALL’s technology



New
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Automated Blood Typing System
IH-500 NEXT
New
Anti-Secukinumab ELISA
LISA-TRACKER anti-Secukinumab
New
Vibrio Cholerae O1/O139 Rapid Test
StrongStep Vibrio Cholerae O1/O139 Antigen Combo Rapid Test

Latest Industry News

Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests